药械

订阅

MedSci主页 / 所有栏目 / 药械

CFDA：批准12个品种为首家中药二级保护品种，11个品种延长保护期

2016-01-25 佚名 医谷

中药保护品种CFDA
关注

1月21日，根据《中药品种保护条例》的规定，CFDA宣布批准了12个中药品种为首家中药二级保护品种，保护期限自公告日起七年，并给予11家企业生产的11个中药保护品种继续给予延长保护期。 同时，CFDA表示，同品种生产企业应按《中药品种保护条例》及有关规定申报同品种保护，逾期不申报的，应停止生产；若继续生产，国家食品药品监督管理总局将中止其批准文号效力，并按《中药品种保护条例》第二十三条的有关

1月21日，根据《中药品种保护条例》的规定，CFDA宣布批准了12个中药品种为首家中药二级保护品种，保护期限自公告日起七年，并给予11家企业生产的11个中药保护品种继续给予延长保护期。

同时，CFDA表示，同品种生产企业应按《中药品种保护条例》及有关规定申报同品种保护，逾期不申报的，应停止生产；若继续生产，国家食品药品监督管理总局将中止其批准文号效力，并按《中药品种保护条例》第二十三条的有关规定进行查处。

中药二级保护品种名单

延长保护期品种名单


 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1782845, encodeId=e8761e8284553, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue May 10 17:04:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890577, encodeId=aa2818905e722, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Nov 08 07:04:00 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60826, encodeId=14f3608263d, content=会有方法的, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:59:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60824, encodeId=dd046082493, content=说到不如做到, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:58:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60825, encodeId=910d608257b, content=加油吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:58:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60638, encodeId=9cb06063843, content=怎样延长保质期？, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-05-10 doctorzheng

    #CFDA:#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1782845, encodeId=e8761e8284553, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue May 10 17:04:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890577, encodeId=aa2818905e722, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Nov 08 07:04:00 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60826, encodeId=14f3608263d, content=会有方法的, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:59:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60824, encodeId=dd046082493, content=说到不如做到, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:58:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60825, encodeId=910d608257b, content=加油吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:58:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60638, encodeId=9cb06063843, content=怎样延长保质期？, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-11-08 stfoxst

    #CFDA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1782845, encodeId=e8761e8284553, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue May 10 17:04:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890577, encodeId=aa2818905e722, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Nov 08 07:04:00 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60826, encodeId=14f3608263d, content=会有方法的, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:59:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60824, encodeId=dd046082493, content=说到不如做到, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:58:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60825, encodeId=910d608257b, content=加油吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:58:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60638, encodeId=9cb06063843, content=怎样延长保质期？, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-27 李继凯

    会有方法的

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1782845, encodeId=e8761e8284553, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue May 10 17:04:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890577, encodeId=aa2818905e722, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Nov 08 07:04:00 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60826, encodeId=14f3608263d, content=会有方法的, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:59:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60824, encodeId=dd046082493, content=说到不如做到, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:58:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60825, encodeId=910d608257b, content=加油吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:58:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60638, encodeId=9cb06063843, content=怎样延长保质期？, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-27 李继凯

    说到不如做到

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1782845, encodeId=e8761e8284553, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue May 10 17:04:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890577, encodeId=aa2818905e722, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Nov 08 07:04:00 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60826, encodeId=14f3608263d, content=会有方法的, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:59:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60824, encodeId=dd046082493, content=说到不如做到, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:58:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60825, encodeId=910d608257b, content=加油吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:58:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60638, encodeId=9cb06063843, content=怎样延长保质期？, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-27 李继凯

    加油吧

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1782845, encodeId=e8761e8284553, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue May 10 17:04:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890577, encodeId=aa2818905e722, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Nov 08 07:04:00 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60826, encodeId=14f3608263d, content=会有方法的, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:59:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60824, encodeId=dd046082493, content=说到不如做到, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:58:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60825, encodeId=910d608257b, content=加油吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 12:58:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60638, encodeId=9cb06063843, content=怎样延长保质期？, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 12:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-27 文医生

    怎样延长保质期？

    0

相关资讯

欢迎澳大利亚对300种中药进行研究

澳大利亚一些大学及科研机构将联合对300种中药进行研究。对于提高中药研究水平，提高中药质量，确保用药安全，有重要意义。也对于促进国际学术交流，提高外国人及外国医学界对中药的正确认识，有重要意义。因此，对这项大兵团作战的重大研究项目应该表示欢迎和关注。但有些问题需要注意。 一、研究对象的选定应该科学、合理。 1、作为研究对象的300种中药，首先应是“合法”中药，是我国食品药品监督管理局正式批准，

药监总局加强中药提取监管 勒令不达标药企停产

针对中药提取环节存在的突出问题，国家食品药品监督管理总局于2014年7月印发了《关于加强中药生产中提取和提取物监督管理的通知》(食药监药化监〔2014〕135号，以下简称135号文件)，明确了中药提取和提取物管理要求并规定了过渡期。自2016年1月1日起，凡不具备相应提取能力的中成药生产企业必须停止生产，生产使用中药提取物必须备案。 自2016年1月1日起，凡不具备相应提取能力的中成药生产企业必

诺奖！立法！中医药国际化正是时机？

12月15日，在广东中医药发展座谈会上，广东省中医药管理局局长徐庆锋指出，要借助这个良好的契机进一步推动中医药国际化进程。广药白云山还设立了“中医药国际化发展基金”，投入2亿元支持旗下中药产品的境外注册、国际市场开拓和国际化合作等工作。 | 中药的国际“身份证”不易拿 中医药国际化一直是中医药产业的宏伟目标之一，早在几百年前，传统中药就曾随着海上丝绸之路走向了全世界。清朝初年，世界

CFDA叫停中药提取委托加工，但行业影响有限

近日，CFDA发布《关于落实中药提取和提取物监督管理有关规定的公告》，要求自今年1月1日起，凡不具备中药前处理和提取能力的中成药生产企业，停止相应中药品种的生产，逾期不停产将依据《药品管理法》严肃查处；同时，生产使用中药提取物必须备案。 “中药提取委托加工被叫停在行业内酝酿已久，也符合预期，且经历了过渡期，落地执行是水到渠成，不会造成‘大震动’。”有行业人士在接受本报记者采访时表示。 据悉

屠呦呦其实不愿给自己出书

14岁时，屠呦呦哥哥送给妹妹的照片。书中插图 屠呦呦11岁时与妈妈合影。 首部全面记录屠呦呦女士过往经历的传记《屠呦呦传》，近日由人民出版社出版。昨天，人民出版社政治一部主任张振明接受采访时透露，一开始屠呦呦是不愿意出这本传记的，“她对名利看得挺淡的，不想宣传自己。后来中国中医科学院的领导劝说她，出这本书不是宣传个人，是让大家看到中国医学的发展和变迁，她才同意出。”

14批次补血制剂复方肝浸膏片被检出高含量铬

新华网北京１２月２５日电　国家食品药品监管总局２５日发布通告称，近日在国家药品抽验中发现，４家企业生产的１４批次复方肝浸膏片（胶囊）检出含有铬成分（胶囊壳铬含量符合规定），有１０批次检出值在３００—１２００ｍｇ／ｋｇ，存在安全风险。 通告称，检出含有铬成分的问题药品是：标示为长治市三宝生化药业有限公司生产的复方肝浸膏片（８批）、山东中泰药业有限公司生产的复方肝浸膏片（３批）、陕西博森生物